Drugs / surinabant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00239174 | Nov 2004 → Nov 2005 | obesity disorder | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00432575 Comparator | Jan 2007 → Apr 2008 | — | Sanofi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | surinabant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00432575 ↗ |
| Known as | SR147778 | “Drug: surinabant (SR147778)” NCT00432575 ↗ |
| Action | Inhibit | “surinabant, a novel selective CB₁ cannabinoid receptor antagonist” PMID 22219220 ↗ Jan 20121“Cannabinoid CB1 receptor antagonist” CHEMBL189676 ↗ |
| Modality | Small molecule | — CHEMBL189676 ↗ |
| Route | Oral | “oral administration” NCT00432575 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor antagonist” CHEMBL189676 ↗ |